Biotechnology

Backed by JLL Partners, new platform Talica aims to unify the fragmented but vital surface science market for aerospace, pharma, and other high-tech industries.

Biotech firm ImmunoScape partners with a top US cancer center for a novel trial, backed by a strategic investment from actor Leonardo DiCaprio.

A new growth medium aims to standardize stem cell production, addressing key regulatory and scalability challenges in the booming regenerative medicine market.

With strong revenue growth and critical FDA decisions on the horizon, MannKind's leadership prepares to outline its vision for investors in Miami.

A new platform by CG Life seeks to redefine rare disease advocacy, using film and storytelling to keep the spotlight on 300 million patients every day.

Fresh off a blockbuster IPO, SpyGlass Pharma heads to a key investor summit. Can its revolutionary long-acting drug platform transform chronic eye care?

After solving a key manufacturing flaw, CervoMed advances its promising dementia drug, neflamapimod, to a Phase 3 trial with an optimized dose.

With its lead drug for a rare blood cancer nearing European submission, Cellectar Biosciences advances its targeted radiotherapy platform on two fronts.

Amid a volatile market, Ligand presents its sustainable growth blueprint, powered by royalties and partnerships, to top investors this March.

A massive $125M investment empowers five international teams to pursue radical ideas, from cancer-proof people to self-destructing tumors.

Theolytics secures a prestigious €8 million EU grant to advance its unique cancer-killing virus, offering new hope for hard-to-treat ovarian cancer.

A new patented drug, budiodarone, aims to treat atrial fibrillation in heart failure patients, a group with few safe options. Is this the future of care?

With record 2025 revenue and a dominant hold on the gene therapy market, Cryoport's strategic investments pave a path toward profitability.

Immunome announces stellar Phase 3 data for its desmoid tumor drug, varegacestat, and details a robust, well-funded ADC pipeline aimed at solid tumors.

The nation's leading aesthetic provider launches a Salmon DNA Facial, XTherma, and NAD+ injections, betting on the science of regenerative beauty.

Finance and governance powerhouse Suzanne Nora Johnson joins Wellcome Leap's board, a strategic move to supercharge its mission to solve health crises.

The D.C. transplant institute surpasses a historic milestone, pioneering new tech and giving thousands a second chance at life amid a national organ shortage.

Biopharma toolmaker Ensorcell appoints Geoff Hodge and Amy Teachout, signaling a strategic move to disrupt the market with affordable, US-made innovation.

A unique $4M award program aims to solve a critical funding gap, accelerating high-risk, high-reward cancer therapies from academic labs to patients.

A new 'scar-less' protein purification technology promises to slash development timelines for complex biologics, accelerating the path to new medicines.